Outcomes of refractory or relapsed DNMT3A~+ cytogenetically normal acute myeloid leukemia patients receiving the therapy including decitabine conbined with CAG or CAG-like regimen
作者:徐妍珺refractorymyeloidregimenreceivingtransplanthematopoieticbridgedmedian
注:因版权方要求,不能公开全文,如需全文,请咨询杂志社